MAP
GPCR icon

Moody Aldrich Partners’s Structure Therapeutics GPCR Stock Holding History

Moody Aldrich Partners’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-27,684
Closed -$1.09M – 205
2024
Q2 		$1.09M Buy
+27,684
New +$1.14M 0.21% 113

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Moody Aldrich Partners's GPCR Position: Q3 2024 in Review

Moody Aldrich Partners sold out of Structure Therapeutics (GPCR) in Q3 2024, closing a stake of 27,684 shares — an estimated $1.09M sold.

Moody Aldrich Partners first reported a position in GPCR in Q2 2024 and held it in 1 quarter. The position peaked at $1.09M in Q2 2024. 160 funds tracked by Wall St. Rank hold GPCR as of Q3 2024.

  • Moody Aldrich Partners reported no remaining Structure Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Moody Aldrich Partners sold 27,684 Structure Therapeutics shares in Q3 2024, an estimated $1.09M.
  • Moody Aldrich Partners first reported a position in Structure Therapeutics in Q2 2024 and held it in 1 quarter.
  • Moody Aldrich Partners's Structure Therapeutics position peaked at $1.09M in Q2 2024.
  • 160 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2024.

Based on Moody Aldrich Partners's 13F filing for Q3 2024, filed 22 Oct 2024.